Lumira Ventures is a venture capital firm in Toronto that focuses on biotechnology, medical technologies, and digital health and consumer healthcare solutions. Founded 1989 in Toronto, Ontario, Canada, it invests in early stage ventures, late stage ventures, post-IPO, private equity, series A, series B, post-IPO equity, and series D rounds. Its portfolio companies include Aurinia Pharmaceuticals, AmacaThera, Satsuma Pharmaceuticals, Bardy Diagnostics, and HistoSonics. As of February 2020, Lumira Ventures has made 62 investments. Their most recent investment was on October 3, 2019, when AmacaThera raised CA$3.6M. Lumira Ventures has had 12 exits, the most notable of which include Zymeworks, Aurinia Pharmaceuticals, and Satsuma Pharmaceuticals. Lumira Ventures has raised fpur funds, their latest being Lumira Ventures III. This fund was announced on June 8, 2017 and raised a total of $178.5M.
A company developing immunotherapy treatments for cancers, infectious and autoimmune diseases
A company that develops tools and techniques to treat heart failure and related conditions
Baye Galligan, M.A., HBA
Benjamin Rovinski, Ph.D.
Brent Norton, MBA
Gerry Brunk, MBA
Lu Han, Ph.D.
Director, Business Development Asia Pacific
Peter van der Velden, MBA, M.Sc.
Managing General Partner
Richard M. Glickman, L.L.D. (Hon)
Documentaries, videos and podcasts